Lack of association between interferon gamma +874 T/A polymorphism and cancer risk: an updated meta-analysis
详细信息 查看全文
- 作者：Yu-Zheng Ge (1)
Yi-Dan Wang (2)
Zheng Xu (1)
Lu-Wei Xu (1)
Ya-Ping Wang (2)
Mao-Hong Gu (2)
Ai-Xing Ding (3)
Xian-Bo Zhu (3)
Ran Wu (1)
Wen-Cheng Li (1)
You-Di Xu (2)
Rui-Peng Jia (1) - 关键词：Interferon gamma ; Polymorphism ; Cancer ; Meta ; analysis
- 刊名：Tumor Biology
- 出版年：2014
- 出版时间：July 2014
- 年：2014
- 卷：35
- 期：7
- 页码：6405-6414
- 全文大小：348 KB
- 参考文献：1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-0. CrossRef
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-4. CrossRef
3. Jin P, Panelli MC, Marincola FM, Wang E. Cytokine polymorphism and its possible impact on cancer. Immunol Res. 2004;30(2):181-0. CrossRef
4. Howell WM, Rose-Zerilli MJ. Cytokine gene polymorphisms, cancer susceptibility, and prognosis. J Nutr. 2007;137(1 Suppl):194S-S.
5. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004;75(2):163-9. CrossRef
6. Billiau A, Matthys P. Interferon-gamma: a historical perspective. Cytokine Growth Factor Rev. 2009;20(2):97-13. CrossRef
7. Schoenborn JR, Wilson CB. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol. 2007;96:41-01. CrossRef
8. Zaidi MR, Merlino G. The two faces of interferon-gamma in cancer. Clin Cancer Res. 2011;17(19):6118-4. CrossRef
9. Bekisz J, Sato Y, Johnson C, Husain SR, Puri RK, Zoon KC. Immunomodulatory effects of interferons in malignancies. J Interferon Cytokine Res. 2013;33(4):154-1. CrossRef
10. Pravica V, Perrey C, Stevens A, Lee JH, Hutchinson IV. A single nucleotide polymorphism in the first intron of the human IFN-gamma gene: absolute correlation with a polymorphic CA microsatellite marker of high IFN-gamma production. Hum Immunol. 2000;61(9):863-. CrossRef
11. Dmitrienko S, Hoar DI, Balshaw R, Keown PA. Immune response gene polymorphisms in renal transplant recipients. Transplantation. 2005;80(12):1773-2. CrossRef
12. Rossouw M, Nel HJ, Cooke GS, van Helden PD, Hoal EG. Association between tuberculosis and a polymorphic NFkappaB binding site in the interferon gamma gene. Lancet. 2003;361(9372):1871-. CrossRef
13. Skerrett DL, Moore EM, Bernstein DS, Vahdat L. Cytokine genotype polymorphisms in breast carcinoma: associations of TGF-beta1 with relapse. Cancer Invest. 2005;23(3):208-4. CrossRef
14. Kamali-Sarvestani E, Merat A, Talei AR. Polymorphism in the genes of alpha and beta tumor necrosis factors (TNF-alpha and TNF-beta) and gamma interferon (IFN-gamma) among Iranian women with breast cancer. Cancer Lett. 2005;223(1):113-.
15. Scola L, Vaglica M, Crivello A, Palmeri L, Forte GI, Macaluso MC, et al. Cytokine gene polymorphisms and breast cancer susceptibility. Ann N Y Acad Sci. 2006;1089:104-. CrossRef
16. Gonullu G, Basturk B, Evrensel T, Oral B, Gozkaman A, Manavoglu O. Association of breast cancer and cytokine gene polymorphism in Turkish women. Saudi Med J. 2007;28(11):1728-3.
17. Karakus N, Kara N, Ulusoy AN, Ozaslan C, Bek Y. Tumor necrosis factor alpha and beta and interferon gamma gene polymorphisms in Turkish breast cancer patients. DNA Cell Biol. 2011;30(6):371-. CrossRef
18. Wu G, Zhang J, Lu P. Association of single nucleotide polymorphism of interferon-gamma gene +874 site and breast cancer. Zhong Liu Fang Zhi Za Zhi. 2008;35(9):651-0.
19. Govan VA, Carrara HR, Sachs JA, Hoffman M, Stanczuk GA, Williamson AL. Ethnic differences in allelic distribution of IFN-g in South African women but no link with cervical cancer. J Carcinog. 2003;2(1):3. CrossRef
20. Guzman VB, Yambartsev A, Goncalves-Primo A, Silva ID, Carvalho CR, Ribalta JC, et al. New approach reveals CD28 and IFNG gene interaction in the susceptibility to cervical cancer. Hum Mol Genet. 2008;17(12):1838-4. CrossRef
21. Gangwar R, Pandey S, Mittal RD. Association of interferon-gamma +874A polymorphism with the risk of developing cervical cancer in north-Indian population. BJOG. 2009;116(12):1671-. CrossRef
22. Ivansson EL, Juko-Pecirep I, Gyllensten UB. Interaction of immunological genes on chromosome 2q33 and IFNG in susceptibility to cervical cancer. Gynecol Oncol. 2010;116(3):544-. CrossRef
23. Wang Q, Zhang C, Walayat S, Chen HW, Wang Y. Association between cytokine gene polymorphisms and cervical cancer in a Chinese population. Eur J Obstet Gynecol Reprod Biol. 2011;158(2):330-. CrossRef
24. do Carmo Vasconcelos de Carvalho V, de Macedo JL, de Lima CA, da Conceicao Gomes de Lima M, de Andrade Heraclio S, Amorim M, et al. IFN-gamma and IL-12B polymorphisms in women with cervical intraepithellial neoplasia caused by human papillomavirus. Mol Biol Rep. 2012;39(7):7627-4. CrossRef
25. Kordi Tamandani MK, Sobti RC, Shekari M, Mukesh M, Suri V. Expression and polimorphism of IFN-gamma gene in patients with cervical cancer. Exp Oncol. 2008;30(3):224-.
26. Wu G, Zhang J, Zuo W. Association between single nucleotide polymorphism of interferon-gamma gene +874 site and susceptibility to ovarian cancer. Journal of Jilin University Medicine Edition. 2009;35(3):507-0.
27. Amirzargar AA, Bagheri M, Ghavamzadeh A, Alimoghadam K, Khosravi F, Rezaei N, et al. Cytokine gene polymorphism in Iranian patients with chronic myelogenous leukaemia. Int J Immunogenet. 2005;32(3):167-1. CrossRef
28. Nearman ZP, Wlodarski M, Jankowska AM, Howe E, Narvaez Y, Ball E, et al. Immunogenetic factors determining the evolution of T-cell large granular lymphocyte leukaemia and associated cytopenias. Br J Haematol. 2007;136(2):237-8. CrossRef
29. Urbanowicz I, Mazur G, Stacherzak-Pawlik J, Bogunia-Kubik K, Wrobel T, Wozniak M, et al. IFN gamma gene polymorphism may contribute to the susceptibility to CLL. Pathol Oncol Res. 2010;16(2):213-. CrossRef
30. Basturk B, Evke E, Tunali A, Karakus S. Interleukin-10 and interferon-gamma cytokine gene polymorphisms may be risk factors for chronic myelogenous leukemia. Turkish Journal of Haematology. 2005;22(4):191-.
31. Basturk B, Evke E, Karakus S, Tunali A. Potential risk factor of interleukin-10 gene polymorphism in acute myelogenous leukemia. UHOD-Uluslararasi Hematoloji-Onkoloji Dergisi. 2005;15(2):57-2.
32. Li J, Cao F, Tang H, Liu X, Zhou J. Study on plasma IFN-gamma expression levels and IFN-gamma polymorphism in patients with acute promyeiocyti leukemia. Zhong Guo You Sheng Yu Yi Chuan Za Zhi. 2008;16(2):39-0.
33. Andrie E, Michos A, Kalampoki V, Pourtsidis A, Moschovi M, Polychronopoulou S, et al. Genetic variants in immunoregulatory genes and risk for childhood lymphomas. Eur J Haematol. 2009;83(4):334-2. CrossRef
34. Howell WM, Turner SJ, Theaker JM, Bateman AC. Cytokine gene single nucleotide polymorphisms and susceptibility to and prognosis in cutaneous malignant melanoma. Eur J Immunogenet. 2003;30(6):409-4. CrossRef
35. Nikolova PN, Pawelec GP, Mihailova SM, Ivanova MI, Myhailova AP, Baltadjieva DN, et al. Association of cytokine gene polymorphisms with malignant melanoma in Caucasian population. Cancer Immunol Immunother. 2007;56(3):371-.
36. Rizzato C, Canzian F, Rudnai P, Gurzau E, Stein A, Koppova K, et al. Interaction between functional polymorphic variants in cytokine genes, established risk factors and susceptibility to basal cell carcinoma of skin. Carcinogenesis. 2011;32(12):1849-4. CrossRef
37. Basturk B, Yavascaoglu I, Vuruskan H, Goral G, Oktay B, Oral HB. Cytokine gene polymorphisms as potential risk and protective factors in renal cell carcinoma. Cytokine. 2005;30(1):41-. CrossRef
38. Omrani M, Bazargani S, Bageri M. Interlukin-10, interferon-(gamma) and tumor necrosis factor-(alpha) genes variation in prostate cancer and benign prostatic hyperplasia. Current Urology. 2008;2(4):175-0. CrossRef
39. Ahirwar DK, Agrahari A, Mandhani A, Mittal RD. Cytokine gene polymorphisms are associated with risk of urinary bladder cancer and recurrence after BCG immunotherapy. Biomarkers. 2009;14(4):213-. CrossRef
40. Nieters A, Yuan JM, Sun CL, Zhang ZQ, Stoehlmacher J, Govindarajan S, et al. Effect of cytokine genotypes on the hepatitis B virus-hepatocellular carcinoma association. Cancer. 2005;103(4):740-. CrossRef
41. Migita K, Miyazoe S, Maeda Y, Daikoku M, Abiru S, Ueki T, et al. Cytokine gene polymorphisms in Japanese patients with hepatitis B virus infection—association between TGF-beta1 polymorphisms and hepatocellular carcinoma. J Hepatol. 2005;42(4):505-0. CrossRef
42. Teixeira AC, Mendes Jr CT, Marano LA, Deghaide NH, Secaf M, Elias Jr J, et al. Alleles and genotypes of polymorphisms of IL-18, TNF-alpha and IFN-gamma are associated with a higher risk and severity of hepatocellular carcinoma (HCC) in Brazil. Hum Immunol. 2013;74(8):1024-. CrossRef
43. Talseth BA, Meldrum C, Suchy J, Kurzawski G, Lubinski J, Scott RJ. Lack of association between genetic polymorphisms in cytokine genes and disease expression in patients with hereditary non-polyposis colorectal cancer. Scand J Gastroenterol. 2007;42(5):628-2. CrossRef
44. Fei B, Lv H, Chen Y, Yang J. Single nucleotide polymorphism of interferon-gamma gene +874 T/A in colorectal cancer. World Chin J Digestol. 2006;14(20):2022-.
45. Du W, Ye W, Chen M, Li D, Jing X. Association research between polymorphism of IFN-gamma and IL-10, environmental risk factors, and susceptibility to esophageal cancer. Wei Sheng Yan Jiu. 2013;42(5):770-.
46. Talar-Wojnarowska R, Gasiorowska A, Smolarz B, Romanowicz-Makowska H, Kulig A, Malecka-Panas E. Tumor necrosis factor alpha and interferon gamma genes polymorphisms and serum levels in pancreatic adenocarcinoma. Neoplasma. 2009;56(1):56-2. CrossRef
47. Farhat K, Hassen E, Gabbouj S, Bouaouina N, Chouchane L. Interleukin-10 and interferon-gamma gene polymorphisms in patients with nasopharyngeal carcinoma. Int J Immunogenet. 2008;35(3):197-05. CrossRef
48. Tai SH, Wei YS, Wang P, Zhou B, Ran P, Yang ZH, et al. Genetic polymorphisms of interferon-gamma and interleukin-8 in patients with nasopharyngeal carcinoma. Sichuan Da Xue Xue Bao Yi Xue Ban. 2007;38(5):862-.
49. Colakogullari M, Ulukaya E, Yilmaztepe Oral A, Aymak F, Basturk B, Ursavas A, et al. The involvement of IL-10, IL-6, IFN-gamma, TNF-alpha and TGF-beta gene polymorphisms among Turkish lung cancer patients. Cell Biochem Funct. 2008;26(3):283-0. CrossRef
50. Mi YY, Yu QQ, Xu B, Zhang LF, Min ZC, Hua LX, et al. Interferon gamma +874 T/A polymorphism contributes to cancer susceptibility: a meta-analysis based on 17 case-control studies. Mol Biol Rep. 2011;38(7):4461-. CrossRef
51. Liu F, Li B, Wei YG, Chen X, Ma Y, Yan LN, et al. IFN-gamma +874 A/T polymorphism and cancer risk: an updated analysis based on 32 case-control studies. Cytokine. 2011;56(2):200-. CrossRef
52. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. CrossRef
53. Ge YZ, Wu R, Jia RP, Liu H, Yu P, Zhao Y, et al. Association between interferon gamma +874 T > A polymorphism and acute renal allograft rejection: evidence from published studies. Mol Biol Rep. 2013;40(10):6043-1. CrossRef
54. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-0. CrossRef
55. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719-8.
56. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-8. CrossRef
57. Wang BS, Liu Z, Xu WX, Sun SL. CYP3A5*3 polymorphism and cancer risk: a meta-analysis and meta-regression. Tumour Biol. 2013;34(4):2357-6. CrossRef
58. Thakkinstian A, McElduff P, D’Este C, Duffy D, Attia J. A method for meta-analysis of molecular association studies. Stat Med. 2005;24(9):1291-06. CrossRef
59. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088-01. CrossRef
60. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-4. CrossRef
61. Slattery ML, Lundgreen A, Bondurant KL, Wolff RK. Interferon-signaling pathway: associations with colon and rectal cancer risk and subsequent survival. Carcinogenesis. 2011;32(11):1660-. CrossRef - 作者单位：Yu-Zheng Ge (1)
Yi-Dan Wang (2)
Zheng Xu (1)
Lu-Wei Xu (1)
Ya-Ping Wang (2)
Mao-Hong Gu (2)
Ai-Xing Ding (3)
Xian-Bo Zhu (3)
Ran Wu (1)
Wen-Cheng Li (1)
You-Di Xu (2)
Rui-Peng Jia (1)
1. Department of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China
2. Department of Obstetrics and Gynecology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China
3. Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing, 210006, China - ISSN：1423-0380
文摘
Interferon gamma (IFN-γ) is a potent proinflammatory cytokine which plays a pivotal role in the antiviral, antiproliferative, and antitumor activities. A T-to-A transition at the position +874 of human IFN-γ gene (IFNG) has been reported to influence the secretion of IFN-γ and affect cancer susceptibility. However, results from published studies on the association between IFNG +874 T/A polymorphism and cancer risk are inconclusive or even controversial. In order to derive a more precise estimation of the association, a meta-analysis of 38 eligible studies including 5,630 cases and 6,096 controls was conducted with odds ratio (OR) and its corresponding 95?% confidence interval (95?% CI). Overall, no significant association was detected in allelic model (A allele vs. T allele—OR--.96, 95?% CI, 0.86-.08), homozygote comparison (AA vs. TT—OR--.97, 95?% CI, 0.79-.21), heterozygote comparison (AT vs. TT—OR--.03, 95?% CI, 0.87-.23), dominant model (AA + AT vs. TT—OR--.00, 95?% CI, 0.87-.15), nor recessive model (AA vs. AT + TT—OR--.93, 95?% CI, 0.78-.12). Further subgroup analyses based on ethnicity, cancer types, and Hardy–Weinberg equilibrium status failed to demonstrate any significant relationship except in African population under recessive model (AA vs. AT + TT—OR--.68, 95?% CI, 0.47-.97). In conclusion, the current meta-analysis suggested that IFNG +874 T/A polymorphism may not contribute to cancer susceptibility, and further well-designed studies with large sample size are warranted to validate our conclusion.